Terms: = Bone cancer AND MAX, MGC36767, 4149, ENSG00000125952, MGC18164, MGC10775, P61244, MGC11225, orf1, MGC34679 AND Prognosis
34 results:
1. Comparison of Baseline
Wu M; Wang Y; Yang Q; Wang X; Yang X; Xing H; Sang X; Li X; Zhao H; Huo L
J Nucl Med; 2023 Oct; 64(10):1532-1539. PubMed ID: 37500263
[TBL] [Abstract] [Full Text] [Related]
2. Super-enhancer-driven MLX mediates redox balance maintenance via SLC7A11 in osteosarcoma.
Guo W; Wang X; Lu B; Yu J; Xu M; Huang R; Cheng M; Yang M; Zhao W; Zou C
Cell Death Dis; 2023 Jul; 14(7):439. PubMed ID: 37460542
[TBL] [Abstract] [Full Text] [Related]
3. Targeting Intratibial Osteosarcoma Using Water-Soluble Copolymers Conjugated to Collagen Hybridizing Peptides.
Subrahmanyam N; Yathavan B; Yu SM; Ghandehari H
Mol Pharm; 2023 Mar; 20(3):1670-1680. PubMed ID: 36724294
[TBL] [Abstract] [Full Text] [Related]
4. Pretreatment [
Gihbid A; Cherkaoui Salhi G; El Alami I; Belgadir H; Tawfiq N; Bendahou K; El Mzibri M; Cadi R; El Benna N; Guensi A; Khyatti M
Ann Nucl Med; 2022 Oct; 36(10):876-886. PubMed ID: 35836088
[TBL] [Abstract] [Full Text] [Related]
5. The Prognostic Value of Posttreatment
Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L
J Nucl Med; 2023 Jan; 64(1):69-74. PubMed ID: 35738906
[No Abstract] [Full Text] [Related]
6.
Wei A; Lu X; Ma H; Lian H; Yang X; Zhang L; Wang D; Chen S; Zhang Q; Li Z; Zhang R; Yang J; Wang T
Contrast Media Mol Imaging; 2022; 2022():4849081. PubMed ID: 35510179
[TBL] [Abstract] [Full Text] [Related]
7. [Pretreatment evaluation of
Peng P; Wu N; Tao XL; Liu Y; Lyu L; Cheng X
Zhonghua Zhong Liu Za Zhi; 2022 Apr; 44(4):370-376. PubMed ID: 35448927
[No Abstract] [Full Text] [Related]
8. The Potential Prognostic Value of Dual-Imaging PET Parameters Based on
Hou J; Long T; Yang Y; Chen D; Hu S
Mol Imaging; 2022; 2022():6511179. PubMed ID: 35368455
[TBL] [Abstract] [Full Text] [Related]
9. The Role of FDG-PET and Whole-Body MRI in High Grade bone Sarcomas With Particular Focus on Osteosarcoma.
Farina A; Gasperini C; Aparisi Gómez MP; Bazzocchi A; Fanti S; Nanni C
Semin Nucl Med; 2022 Sep; 52(5):635-646. PubMed ID: 34879906
[TBL] [Abstract] [Full Text] [Related]
10. Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials.
Jamet B; Morvan L; Nanni C; Michaud AV; Bailly C; Chauvie S; Moreau P; Touzeau C; Zamagni E; Bodet-Milin C; Kraeber-Bodéré F; Mateus D; Carlier T
Eur J Nucl Med Mol Imaging; 2021 Apr; 48(4):1005-1015. PubMed ID: 33006656
[TBL] [Abstract] [Full Text] [Related]
11. Tumor metabolic volume by
Yamaguchi O; Kaira K; Hashimoto K; Mouri A; Shiono A; Miura Y; Murayama Y; Kobayashi K; Kagamu H; Kuji I
Sci Rep; 2020 Sep; 10(1):14990. PubMed ID: 32929123
[TBL] [Abstract] [Full Text] [Related]
12. Impact of Anatomic Location of bone Metastases on prognosis in Metastatic Castration-Resistant Prostate cancer.
Roth AR; Harmon SA; Perk TG; Eickhoff J; Choyke PL; Kurdziel KA; Dahut WL; Apolo AB; Morris MJ; Perlman SB; Liu G; Jeraj R
Clin Genitourin Cancer; 2019 Aug; 17(4):306-314. PubMed ID: 31221545
[TBL] [Abstract] [Full Text] [Related]
13. Lesion detection by [
Verhoeff SR; van Es SC; Boon E; van Helden E; Angus L; Elias SG; Oosting SF; Aarntzen EH; Brouwers AH; Kwee TC; Heskamp S; Hoekstra OS; Verheul H; van der Veldt AAM; de Vries EGE; Boerman OC; van der Graaf WTA; Oyen WJG; van Herpen CML
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1931-1939. PubMed ID: 31172212
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic value of 68 Ga PSMA I&T PET/CT SUV parameters on survival outcome in advanced prostat cancer.
Komek H; Can C; Yilmaz U; Altindag S
Ann Nucl Med; 2018 Oct; 32(8):542-552. PubMed ID: 30006752
[TBL] [Abstract] [Full Text] [Related]
15. Relationship of peak serum methotrexate concentration to prognosis and drug tolerance in non-metastatic extremity osteosarcomas.
Wang B; Yao H; Xie X; Yin J; Zou C; Huang G; Shen J
Cancer Chemother Pharmacol; 2018 Aug; 82(2):221-227. PubMed ID: 29808416
[TBL] [Abstract] [Full Text] [Related]
16. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcoma.
Akin S; Dizdar O; Karakas Y; Turker A; Kars A
Curr Probl Cancer; 2018; 42(3):344-349. PubMed ID: 29576383
[TBL] [Abstract] [Full Text] [Related]
17. Vertebral metastases from neuroendocrine tumours: How to avoid false positives on
Gauthé M; Testart Dardel N; Ruiz Santiago F; Ohnona J; Nataf V; Montravers F; Talbot JN
Eur Radiol; 2018 Sep; 28(9):3943-3952. PubMed ID: 29532242
[TBL] [Abstract] [Full Text] [Related]
18. Standard diffusion-weighted, diffusion kurtosis and intravoxel incoherent motion MR imaging of sinonasal malignancies: correlations with Ki-67 proliferation status.
Xiao Z; Zhong Y; Tang Z; Qiang J; Qian W; Wang R; Wang J; Wu L; Tang W; Zhang Z
Eur Radiol; 2018 Jul; 28(7):2923-2933. PubMed ID: 29383521
[TBL] [Abstract] [Full Text] [Related]
19. Oncological and functional results after surgical treatment of bone metastases at the proximal femur.
Guzik G
BMC Surg; 2018 Jan; 18(1):5. PubMed ID: 29370790
[TBL] [Abstract] [Full Text] [Related]
20. Smoldering mantle cell lymphoma.
Ye H; Desai A; Zeng D; Nomie K; Romaguera J; Ahmed M; Wang ML
J Exp Clin Cancer Res; 2017 Dec; 36(1):185. PubMed ID: 29246179
[TBL] [Abstract] [Full Text] [Related]
[Next]
